Press release
Nov 19, 2019

Sosei Heptares creates new world-class international Scientific Advisory Board to support strategic decision-making aligned with corporate objectives


Tokyo, Japan and London, UK, 19 November 2019 – Sosei Group Corporation (“the Company”; TSE: 4565) announces the formation of a new Scientific Advisory Board (SAB) to advise on the Company’s scientific strategy in support of its corporate objectives.

The SAB includes world-leading experts from academia and the pharmaceutical industry in the US and Europe, each of whom is highly regarded in their respective fields. Collectively, the SAB will provide valuable insight and perspective relevant to strategic areas of focus for Sosei Heptares. These relate to extending its leadership advantage in G protein-coupled receptor (GPCR) structure-based drug design and capitalizing on the value-generation potential of this and its pipeline of novel drug candidates. Brief biographies are below and more information is available on the Sosei Heptares website.

The SAB includes:

Dr. David Roblin (Chair), former Senior VP and Head of R&D for Pfizer in Europe and Director of Scientific Translation at the Francis Crick Institute (London, UK); current President of R&D at Summit Therapeutics plc (Oxford, UK); Board Director of Sosei Group Corporation.

Dr. Peter Bernstein, a drug discovery and development consultant with more than 30 years’ experience working with AstraZeneca and its previous incarnations; advanced multiple compounds into development.

Prof. Ed Bullmore, Head of the Department of Psychiatry and Director of the Wolfson Brian Imaging Centre (University of Cambridge, UK); former VP Experimental Medicine at GlaxoSmithKline (GSK).

Prof. Richard Henderson, a structural biologist/biophysicist and pioneer in the field of electron microscopy (EM) of biological molecules, such as GPCRs; based at the MRC Laboratory of Molecular Biology (MRC LMB; Cambridge, UK) and a co-founder of Heptares Therapeutics; shared the Nobel Prize in Chemistry in 2017 with Jacques Dubochet and Joachim Frank for his work on cryo-EM.

Dr. Paul Leeson, a medicinal chemistry consultant with more than 35 years’ experience in pharmaceutical companies, including AstraZeneca, GSK, Merck & Co and Wyeth, leading to advances in drug discovery in cardiovascular, neuroscience, respiratory and inflammation.

Prof. Sir Keith Peters, former Regius Professor of Physic and Head of the Clinical School at the University of Cambridge, UK; formerly a senior advisor to Merck & Co, Amersham plc, and GSK; knighted for services to medicine in 1993 and made GBE (Knight Grand Cross of the Order of the British Empire) in 2018 for services to the advancement of medical sciences.

Dr. Caetano Reis e Sousa, Assistant Research Director and Senior Group Leader of the Immunobiology Laboratory at The Francis Crick Institute and Professor of Immunology at Imperial College London.

Dr. Darryle Schoepp, a research consultant with over 30 years’ experience in the discovery and development of innovative neuroscience therapeutics leading research and therapeutic area teams at Eli Lilly and Merck & Co.

Dr. Roberto Solari, Visiting Professor at the National Heart & Lung Institute (Imperial College London); formerly at GlaxoSmithKline and MRCT, the technology transfer arm of the UK Medical Research Council.

Dr. Christopher Tate, a membrane protein biochemist at the MRC LMB who pioneered the use of conformational thermostabilization for the structure determination of GPCRs; co-founder of Heptares Therapeutics.

Mr. Anders Tullgren, a consultant/advisor to pharmaceutical and biotechnology companies and private equity firms; over 20 years in commercial leadership roles at Bristol-Myers Squibb around the world.

Dr. Malcolm Weir, Executive Vice President Research and Early Development of Sosei Heptares, said: “We are delighted to have assembled such an outstanding Scientific Advisory Board. Each member has been selected based on the world-class expertise and experience they can bring to support our scientific strategy as a fundamental driver of our corporate activities. Their insights and advice will be crucial to our strategic decision-making processes as we continue to create value from our leading GPCR-focused drug discovery and development capabilities."

 

–        ENDS –


 DOWNLOAD PDF